552 related articles for article (PubMed ID: 16555999)
1. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
3. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
4. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
6. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
Yun BG; Matts RL
Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
11. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
12. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
13. Hsp90: an emerging target for breast cancer therapy.
Beliakoff J; Whitesell L
Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
[TBL] [Abstract][Full Text] [Related]
14. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
15. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
Blagosklonny MV
Leukemia; 2002 Apr; 16(4):455-62. PubMed ID: 11960322
[TBL] [Abstract][Full Text] [Related]
16. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Guo F; Rocha K; Bali P; Pranpat M; Fiskus W; Boyapalle S; Kumaraswamy S; Balasis M; Greedy B; Armitage ES; Lawrence N; Bhalla K
Cancer Res; 2005 Nov; 65(22):10536-44. PubMed ID: 16288046
[TBL] [Abstract][Full Text] [Related]
17. HSP90 as a new therapeutic target for cancer therapy: the story unfolds.
Maloney A; Workman P
Expert Opin Biol Ther; 2002 Jan; 2(1):3-24. PubMed ID: 11772336
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic and diagnostic implications of Hsp90 activation.
Kamal A; Boehm MF; Burrows FJ
Trends Mol Med; 2004 Jun; 10(6):283-90. PubMed ID: 15177193
[TBL] [Abstract][Full Text] [Related]
19. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
20. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.
Gossett DR; Bradley MS; Jin X; Lin J
Gynecol Oncol; 2005 Feb; 96(2):381-8. PubMed ID: 15661225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]